Bringing you the latest cutting-edge research and commentary in bioscience.

Cell & Gene Therapy Insights

Cell & Gene Therapy Insights

Innovator Insight
Spotlight Article

Development and validation of quantitative real-time PCR for the detection of residual HEK-293 host cell DNA

Viral vector bioprocessing & analytics: today’s key tools and innovation requirements to meet future demand

Kara Norman

The presence of residual DNA in therapy products may lead to an increased risk of oncogenicity, immunogenicity, and other toxicity. Current regulatory authorities (including the US FDA, EMA and WHO) limited the accepted amounts of residual DNA in biological products making it extremely important to have a sensitive method of quantifying residual host cell DNA. Among the methods of detecting residual DNA, quantitative polymerase chain reaction (qPCR) is the most widely used for residual DNA quantitation due to its sensitivity, accuracy, precision, and time-saving capability. This article examines the development and validation of a new, highly sensitive and accurate integrated solution for detection and quantitation of low level HEK-293 DNA to help meet regulatory requirements.

DOI: 10.18609/cgti.2020.054
Citation: Cell & Gene Therapy Insights 2020; 6(3), 439–448
Open access

Thermo Fisher Scientific logo

Twitter IconVisit Our Blog